KUKE
đźš« does not pay dividends

Company News

12 Communication Services Stocks Moving In Friday's Pre-Market Session
Benzinga • Benzinga Staff Writer • September 26, 2025

Multiple communication services stocks experienced significant pre-market price movements, with some companies seeing notable gains and others experiencing declines.

Kuke Announces Plan to Implement ADS Ratio Change
GlobeNewswire Inc. • N/A • March 3, 2025

Kuke Music Holding Limited, a leading classical music service platform in China, announced a change in the ratio of its American depositary shares (ADSs) to its Class A ordinary shares from 1:1 to 1:10, effective March 13, 2025. This change will have no impact on the underlying Class A ordinary shares.

Kuke and Jidou Join Forces in the AI Music Market
GlobeNewswire Inc. • Kuke Music Holding Limited • June 14, 2024

Beijing, June 14, 2024 (GLOBE NEWSWIRE) -- Kuke Music Holding Limited ("Kuke" or the "Company") (NYSE: KUKE), a leading classical music service platform in China with approximately 3 million audio and video music tracks, recently announced its entry into the AI music field and the integration of its AI music technology into automobiles. The Co...

KUKE Announces Purchase Terms with Naxos One
GlobeNewswire Inc. • Kuke Music Holding Limited • May 24, 2024

BEIJING, May 24, 2024 (GLOBE NEWSWIRE) -- Kuke Music Holdings Limited (“Kuke” or the “Company”) (NYSE: KUKE), the leading classical music service platform in China, is pleased to announce that on May 24, 2024, it has signed a non-binding term sheet (the “Term Sheet”) with Naxos One Holding Limited (“Naxos One”), a limited liabil...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga • Avi Kapoor • April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...

Related Companies